Apellis Pharmaceuticals Inc

NASDAQ:APLS   3:59:52 PM EDT
45.41
+0.19 (+0.42%)
Products, Strategic Combinations

Apellis Expands Collaboration With Affilogic To Develop Targeted Complement Therapies For Delivery Into The Brain

Published: 06/22/2022 11:31 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis Expands Research and Development Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery Into the Brain.
Apellis Pharmaceuticals Inc - Secured Exclusive, Sublicensable, Worldwide Patent Rights for All Development Projects.
Apellis Pharma-affilogic to Be Eligible to Get Development Milestone Payments,royalty Payments on Net Sales of Any Product Approved Out of Collaboration.